Innovative virus-based vaccine / 2026
A local barrier against respiratory viruses
How can a respiratory virus be stopped before it spreads throughout the body? In the MucoShield project, Prime Vector Technologies, the NMI Tübingen, and Fraunhofer IGB are developing an intranasal vaccine candidate against human metapneumovirus (HMPV), which causes hundreds of thousands of cases of severe respiratory disease worldwide each year – especially among children, older people, and immunocompromised individuals. The novel approach: A mucoadhesive formulation is designed to activate the immune response directly at the virus’s point of entry – the nasal mucosa.
more info